3057 Is there difference in the efficacy of first-line gefitinib according to the type of EGFR mutations in non-small cell lung cancer?

Authors :: M.S. Ahn
Y.W. Choi
Jin Hwa Choi
Seok Yun Kang
Hyun Woong Lee
So Yeon Jeon
Source :: European Journal of Cancer. 51:S614-S615
Publication Year :: 2015
Publisher :: Elsevier BV, 2015.

Subjects :: Cancer Research
Gefitinib
Oncology
Egfr mutation
business.industry
First line
Cancer research
medicine
Non small cell
Lung cancer
medicine.disease
business
medicine.drug

Full Text Access

Tools